We seek opportunities to enhance our patients’ futures

At Intercept, our mission is to translate bile acid research into promising new treatments for liver diseases.


At Intercept, our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options.

About Intercept

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing our proprietary bile acid chemistry.

Our product candidates have the potential to treat orphan and more prevalent diseases for which there currently are limited therapeutic solutions.

Obeticholic acid (OCA)—an FXR agonist

OCA Molecule

  • OCA is a lead product candidate that
    • Selectively binds to and activates the farnesoid X receptor (FXR)
    • Regulates liver, intestinal, and kidney function
    • Modulates inflammatory, metabolic, and immune pathways
  • Intercept is developing OCA in primary biliary cirrhosis (PBC)* for patients
    • With an inadequate response to standard-of-care therapy
    • Unable to tolerate standard-of-care therapy
  • PBC is a chronic, autoimmune, cholestatic liver disease
    • If inadequately treated, it may eventually lead to cirrhosis, liver failure, and death

Intercept owns worldwide rights to OCA outside of Japan, Korea, and China, where we have exclusively licensed the compound to Sumitomo Dainippon, and granted it an option to exclusively license OCA in certain other Asian countries.

*Also known as primary biliary cholangitis.


Find out more about our outstanding leadership.

Board of Directors

Learn more about our industry-leading board of directors.

Contact Us

Contact Intercept for job, media, investor, or partnering inquiries.

You are now being redirected to Intercept’s job application site, hosted by Pereless Systems.